Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 17/20 | 0.83 |
| ▸ | PPARG | P37231 | 1/20 | 0.83 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.49 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.48 |
| ▸ | LTK | P29376 | 1/20 | 0.48 |
| ▸ | TAOK1 | Q7L7X3 | 1/20 | 0.48 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.48 |
| ▸ | MMP1 | P03956 | 1/20 | 0.44 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1604202 | 0.91 | FFAR1 (1.00) | FFAR1PPARGHPGDNR4A2S1PR1 | |
| SCHEMBL1584485 | 0.91 | FFAR1 (1.00) | FFAR1PPARGHPGDNR4A2S1PR1 | |
| SCHEMBL12708067 | 0.84 | FFAR1 (0.61) | FFAR1PPARG | |
| SCHEMBL12708026 | 0.83 | FFAR1 (0.82) | FFAR1PPARG | |
| SCHEMBL12708021 | 0.82 | FFAR1 (0.57) | FFAR1PPARGS1PR1S1PR5 | |
| SCHEMBL12708016 | 0.80 | FFAR1 (0.84) | FFAR1PPARGS1PR1S1PR5 | |
| SCHEMBL12708013 | 0.80 | FFAR1 (0.58) | FFAR1PPARG | |
| SCHEMBL12708020 | 0.78 | FFAR1 (0.65) | FFAR1PPARG | |
| SCHEMBL12708066 | 0.78 | FFAR1 (0.64) | FFAR1PPARG | |
| SCHEMBL18878515 | 0.77 | FFAR1 (0.53) | FFAR1PPARGHPGDNR4A2S1PR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8288404-B2 | Pyrrolidine GPR40 modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-10-16 | — | — | US | disclosed |
| US-20110082165-A1 | PYRROLIDINE GPR40 MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2011-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110082165-A1 | PYRROLIDINE GPR40 MODULATORS | GPR55, GPR65, GPR27 | FFAR1 37/4885PPARG 69/4885HPGD 743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.